Lower levels of Acat2 activity in the human liver can delay the development of atherosclerosis (Parini et al., 2004); therefore, improving the stability of Acat2 may be an effective treatment strategy for type II diabetes (Wang et al., 2017). Here, ACAT2 is linked to atherosclerosis.